Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q2 2015 · 10-Q
Revenue$36.34M$36.34M+17.2% vs Q2 2014 Net Income-$7.49M-$7.49MN/M vs Q2 2014 EPS Diluted-$49.26-$49.26N/M vs Q2 2014 Gross Profit$402,000−92.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,523,000N/M Free Cash Flowderived-$2,601,000N/M Margins · derivedGross margin1.1%−15.6 pt vs Q2 2014
Operating margin-21.2%−17.8 pt vs Q2 2014
Net margin-20.6%−12.0 pt vs Q2 2014
ended Jun 30, 2015 · filed Aug 14, 2015 · 45 d after period end